Multiplex PCR Assay for C. difficile Strain Characterization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack an efficient and comprehensive approach for detecting and characterizing toxinogenic Clostridium difficile strains, particularly the hypervirulent NAP1/BI/027, ribotype 078, and 017 strains, which are responsible for severe infections and outbreaks.
Innovation Solution
A multiplex PCR assay that analyzes samples for the presence of specific gene deletions and toxin genes, including the cytotoxin tcdB gene, tcdC gene deletions, and binary toxin cdtA/B genes, allowing for simultaneous scoring of toxinogenic Clostridium difficile strains and differentiation between various virulent types.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If multiple separate detection methods are used for different C. difficile strains and toxins, then comprehensive detection coverage is achieved, but detection time and procedural complexity increase
Solution Approach 1:
The patent combines multiple detection targets (tcdC gene deletions, tcdB toxin gene, and strain-specific markers for NAP1/BI/027, ribotype 078, and 017 strains) into a single multiplex PCR assay. This allows simultaneous detection of various C. difficile strains and their toxinogenic potential in one reaction, achieving comprehensive detection coverage while reducing detection time and procedural complexity compared to performing separate assays for each target.
Solution Approach 2:
The detection method is designed as a universal platform that can identify multiple C. difficile strains and toxin genes using a single multiplex PCR protocol. The assay universally detects the tcdC gene deletions associated with toxin production and simultaneously identifies specific hypervirulent strains, eliminating the need for multiple specialized tests and streamlining the diagnostic workflow.
2Measurement precision
If comprehensive genetic analysis of multiple toxin genes and deletions is performed, then strain characterization accuracy is improved, but assay complexity increases
Solution Approach 1:
The patent integrates analysis of multiple genetic targets (tcdC gene deletions at positions 117, 330-347, and 301-336; tcdB toxin gene; and strain-specific markers) into a single multiplex PCR reaction. By combining these detection targets in one assay, the method achieves accurate strain characterization while minimizing assay complexity compared to performing separate PCR reactions for each genetic element.
Solution Approach 2:
The multiplex PCR assay is designed with distinct primer sets and detection conditions for different genetic targets within the same reaction. Each target (tcdC deletions, tcdB gene, strain-specific markers) is detected through segmented analysis using specific primers and probes, allowing precise characterization of multiple strain features simultaneously without overwhelming assay complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables accurate and simultaneous detection and characterization of toxinogenic Clostridium difficile strains, including hypervirulent types, facilitating early intervention and aggressive management of infections.
Implementation Method 1
In a multiplex PCR assay, the sample is analyzed with respect to the presence or absence of the cytotoxin tcdB gene
Data Source
AI summary
The invention relates to a cartridge for the detection and characterization of a toxinogenic Clostridium difficile strain in a sample, wherein the following steps are performed, (i) a sample is provided for, (ii) in a multiplex PCR assay, (iii) the sample is analyzed with respect to the presence or absence of the cytotoxin tcdB gene, (iv) the sample is analyzed with respect to the presence or absence of one or more of the following deletions in the tcdC gene: (a) an 18 bp deletion in SEQ ID NO. 1 from nucleotide 330 to nucleotide 347, (b) a 36 bp deletion in SEQ ID NO. 1 from nucleotide 301 to nucleotide 336, (c) a 39 bp deletion in SEQ ID NO. 1 from nucleotide 341 to nucleotide 370, (d) a 54 bp deletion in SEQ ID NO. 1 from nucleotide 313 to nucleotide 366 and (e) a single nucleotide deletion at position 117 of SEQ ID NO. 1. The invention also relates to respective kits and primers and probes.